Arrowhead Pharmaceuticals, Inc. (ARWR)
85.37
+2.63
(+3.18%)
USD |
NASDAQ |
Sep 02, 16:00
85.13
-0.24
(-0.28%)
After-Hours: 06:00
Arrowhead Pharmaceuticals Cash from Investing (Quarterly) : 43.68M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 43.68M |
| March 31, 2026 | -894.28M |
| December 31, 2025 | -23.74M |
| September 30, 2025 | 72.62M |
| June 30, 2025 | 141.39M |
| March 31, 2025 | -420.21M |
| December 31, 2024 | 76.91M |
| September 30, 2024 | -222.92M |
| June 30, 2024 | 6.949M |
| March 31, 2024 | -268.94M |
| December 31, 2023 | 64.84M |
| September 30, 2023 | 30.51M |
| June 30, 2023 | -9.905M |
| March 31, 2023 | -36.06M |
| December 31, 2022 | -80.69M |
| September 30, 2022 | 36.44M |
| June 30, 2022 | 61.28M |
| March 31, 2022 | -69.76M |
| December 31, 2021 | -33.38M |
| September 30, 2021 | -118.24M |
| June 30, 2021 | -19.54M |
| March 31, 2021 | -34.05M |
| December 31, 2020 | 30.16M |
| September 30, 2020 | -65.89M |
| June 30, 2020 | -6.034M |
| Date | Value |
|---|---|
| March 31, 2020 | -178.13M |
| December 31, 2019 | 9.280M |
| September 30, 2019 | 16.83M |
| June 30, 2019 | 14.40M |
| March 31, 2019 | -11.22M |
| December 31, 2018 | -67.76M |
| September 30, 2018 | 3.247M |
| June 30, 2018 | -28.85M |
| March 31, 2018 | 16.82M |
| December 31, 2017 | 1.357M |
| September 30, 2017 | -4.219M |
| June 30, 2017 | -12.93M |
| March 31, 2017 | -26.20M |
| December 31, 2016 | -5.297M |
| September 30, 2016 | -1.712M |
| June 30, 2016 | 9.461M |
| March 31, 2016 | 3.106M |
| December 31, 2015 | 2.593M |
| September 30, 2015 | 5.845M |
| June 30, 2015 | 3.977M |
| March 31, 2015 | 8.799M |
| December 31, 2014 | -4.500M |
| September 30, 2014 | 4.545M |
| June 30, 2014 | 0.9364M |
| March 31, 2014 | -26.82M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Sarepta Therapeutics, Inc. | -93.37M |
| Revolution Medicines, Inc. | -1.659B |
| Moderna, Inc. | 329.00M |
| Intellia Therapeutics, Inc. | -141.57M |
| Denali Therapeutics, Inc. | -104.08M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -177.47M |
| Cash from Financing (Quarterly) | -0.449M |
| Free Cash Flow | -75.11M |
| Free Cash Flow Per Share (Quarterly) | -1.265 |
| Free Cash Flow to Equity (Quarterly) | -184.24M |
| Free Cash Flow to Firm (Quarterly) | -156.76M |
| Free Cash Flow Yield | -0.63% |